http://www.livemint.com/Companies/zcSsHW6iNvlulIW5K1qk9N/The-Rs1-trillion-FDA-impact-on-Indian-pharma.html
Mumbai: The market capitalization of India’s top five pharma companies, Sun Pharmaceutical Industries Ltd, Dr Reddy’s Laboratories Ltd, Cipla Ltd, Lupin Ltd and Wockhardt Ltd, have fallen by Rs.99,235 crore between the time their stocks touched their peaks in the past year, and Monday.
Much of the fall can be attributed to warnings and import alerts issued by the US Food and Drug Administration (US FDA) on manufacturing plants of the five companies. The US is the world’s largest generics (or off-patent drugs) market, and an important source of business for most Indian pharma companies.
On 26 September, the US FDA revoked permission it had given Sun Pharma’s subsidiary Sun Pharma Advanced Research Company Ltd (SPARC) to launch an epilepsy drug. SPARC planned to manufacture the drug at Sun Pharma’s Halol facility, and while the US FDA didn’t have any problems with this at the time it granted its approval (despite its earlier warning regarding Halol), it did find “the compliance status of the manufacturing facility was not acceptable on the date of approval”, according to SPARC, which also added that Sun Pharma was working to fix the problems
trailing pe
sun 58
cipla 30 (a bargain, really)
dr reddy 164 (grandkids, grandkids lifetime)
wockhardt 36
lupin 39
guessing buy cipla, wockhardt, lupin (basket) sell reddy (basket
Comments